20 June 2013
Keywords: seragen, ph, iii, il-2, fusion, toxin, trials
Article | 02 January 1995
Seragen has started the Phase III clinical trials program for its
interleukin-2 fusion toxin product for the treatment of cutaneous ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscriptions are £60 per month, pay as you go.
Find out more details.
2 January 1995
9 January 1995
19 June 2013
© 2013 thepharmaletter.com